Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of experimental medicine 2020-09, Vol.217 (9)
Hauptverfasser:	Koenig, Lars M, Boehmer, Daniel F R, Metzger, Philipp, Schnurr, Max, Endres, Stefan, Rothenfusser, Simon
Format:	Artikel
Sprache:	eng
Schlagworte:	Betacoronavirus Coronavirus Infections - epidemiology COVID-19 Humans Infectious Disease and Host Defense Inflammation Innate Immunity and Inflammation Pandemics Pneumonia, Viral SARS-CoV-2 Viewpoint
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue	9
container_start_page
container_title	The Journal of experimental medicine
container_volume	217
creator	Koenig, Lars M Boehmer, Daniel F R Metzger, Philipp Schnurr, Max Endres, Stefan Rothenfusser, Simon
description	An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
doi_str_mv	10.1084/jem.20201342
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7365736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2424998784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-a79b838f532c82de76c272c504f8aba3adb0be56e3431c8b7cc0cdf1a1067eea3</originalsourceid><addsrcrecordid>eNpVUU1Lw0AQXUSxtXrzLHv0YHT2I8nGg6DxEwShqHhbJttNjSbZmt0q_ntTW0VhhoE3jzePeYTsMjhkoOTRi20OOXBgQvI1MmSxhCiLhVonQwDOIwaQDsiW9y8ATMo42SQDwZNUScGHRJ_VzrxW7ZRWbVlj02CoXEv7Cs-WfuDnMR1_Q1hbWrqO5k_5mFNsA05dW_ngv9EFOXQWQ2PbQF1J87vHm_OIZdtko8Ta253VHJGHy4v7_Dq6vbu6yU9vIyNjCBGmWaGEKmPBjeITmyaGp9zEIEuFBQqcFFDYOLFCCmZUkRoDZlIyZJCk1qIYkZOl7mxeNHZiehsd1nrWVQ12n9phpf9v2upZT927TkUS990L7K8EOvc2tz7opvLG1jW21s295pLLLFOLt43IwZJqOud9Z8vfMwz0IhPdZ6J_Munpe3-t_ZJ_QhBfwp-Ieg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424998784</pqid></control><display><type>article</type><title>Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Koenig, Lars M ; Boehmer, Daniel F R ; Metzger, Philipp ; Schnurr, Max ; Endres, Stefan ; Rothenfusser, Simon</creator><creatorcontrib>Koenig, Lars M ; Boehmer, Daniel F R ; Metzger, Philipp ; Schnurr, Max ; Endres, Stefan ; Rothenfusser, Simon</creatorcontrib><description>An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.</description><identifier>ISSN: 0022-1007</identifier><identifier>EISSN: 1540-9538</identifier><identifier>DOI: 10.1084/jem.20201342</identifier><identifier>PMID: 32678432</identifier><language>eng</language><publisher>United States: Rockefeller University Press</publisher><subject>Betacoronavirus ; Coronavirus Infections - epidemiology ; COVID-19 ; Humans ; Infectious Disease and Host Defense ; Inflammation ; Innate Immunity and Inflammation ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; Viewpoint</subject><ispartof>The Journal of experimental medicine, 2020-09, Vol.217 (9)</ispartof><rights>2020 Koenig et al.</rights><rights>2020 Koenig et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-a79b838f532c82de76c272c504f8aba3adb0be56e3431c8b7cc0cdf1a1067eea3</citedby><cites>FETCH-LOGICAL-c450t-a79b838f532c82de76c272c504f8aba3adb0be56e3431c8b7cc0cdf1a1067eea3</cites><orcidid>0000-0002-8348-7787 ; 0000-0002-4703-537X ; 0000-0001-6538-2474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32678432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koenig, Lars M</creatorcontrib><creatorcontrib>Boehmer, Daniel F R</creatorcontrib><creatorcontrib>Metzger, Philipp</creatorcontrib><creatorcontrib>Schnurr, Max</creatorcontrib><creatorcontrib>Endres, Stefan</creatorcontrib><creatorcontrib>Rothenfusser, Simon</creatorcontrib><title>Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19</title><title>The Journal of experimental medicine</title><addtitle>J Exp Med</addtitle><description>An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.</description><subject>Betacoronavirus</subject><subject>Coronavirus Infections - epidemiology</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Infectious Disease and Host Defense</subject><subject>Inflammation</subject><subject>Innate Immunity and Inflammation</subject><subject>Pandemics</subject><subject>Pneumonia, Viral</subject><subject>SARS-CoV-2</subject><subject>Viewpoint</subject><issn>0022-1007</issn><issn>1540-9538</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1Lw0AQXUSxtXrzLHv0YHT2I8nGg6DxEwShqHhbJttNjSbZmt0q_ntTW0VhhoE3jzePeYTsMjhkoOTRi20OOXBgQvI1MmSxhCiLhVonQwDOIwaQDsiW9y8ATMo42SQDwZNUScGHRJ_VzrxW7ZRWbVlj02CoXEv7Cs-WfuDnMR1_Q1hbWrqO5k_5mFNsA05dW_ngv9EFOXQWQ2PbQF1J87vHm_OIZdtko8Ta253VHJGHy4v7_Dq6vbu6yU9vIyNjCBGmWaGEKmPBjeITmyaGp9zEIEuFBQqcFFDYOLFCCmZUkRoDZlIyZJCk1qIYkZOl7mxeNHZiehsd1nrWVQ12n9phpf9v2upZT927TkUS990L7K8EOvc2tz7opvLG1jW21s295pLLLFOLt43IwZJqOud9Z8vfMwz0IhPdZ6J_Munpe3-t_ZJ_QhBfwp-Ieg</recordid><startdate>20200907</startdate><enddate>20200907</enddate><creator>Koenig, Lars M</creator><creator>Boehmer, Daniel F R</creator><creator>Metzger, Philipp</creator><creator>Schnurr, Max</creator><creator>Endres, Stefan</creator><creator>Rothenfusser, Simon</creator><general>Rockefeller University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8348-7787</orcidid><orcidid>https://orcid.org/0000-0002-4703-537X</orcidid><orcidid>https://orcid.org/0000-0001-6538-2474</orcidid></search><sort><creationdate>20200907</creationdate><title>Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19</title><author>Koenig, Lars M ; Boehmer, Daniel F R ; Metzger, Philipp ; Schnurr, Max ; Endres, Stefan ; Rothenfusser, Simon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-a79b838f532c82de76c272c504f8aba3adb0be56e3431c8b7cc0cdf1a1067eea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Betacoronavirus</topic><topic>Coronavirus Infections - epidemiology</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Infectious Disease and Host Defense</topic><topic>Inflammation</topic><topic>Innate Immunity and Inflammation</topic><topic>Pandemics</topic><topic>Pneumonia, Viral</topic><topic>SARS-CoV-2</topic><topic>Viewpoint</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koenig, Lars M</creatorcontrib><creatorcontrib>Boehmer, Daniel F R</creatorcontrib><creatorcontrib>Metzger, Philipp</creatorcontrib><creatorcontrib>Schnurr, Max</creatorcontrib><creatorcontrib>Endres, Stefan</creatorcontrib><creatorcontrib>Rothenfusser, Simon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koenig, Lars M</au><au>Boehmer, Daniel F R</au><au>Metzger, Philipp</au><au>Schnurr, Max</au><au>Endres, Stefan</au><au>Rothenfusser, Simon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19</atitle><jtitle>The Journal of experimental medicine</jtitle><addtitle>J Exp Med</addtitle><date>2020-09-07</date><risdate>2020</risdate><volume>217</volume><issue>9</issue><issn>0022-1007</issn><eissn>1540-9538</eissn><abstract>An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.</abstract><cop>United States</cop><pub>Rockefeller University Press</pub><pmid>32678432</pmid><doi>10.1084/jem.20201342</doi><orcidid>https://orcid.org/0000-0002-8348-7787</orcidid><orcidid>https://orcid.org/0000-0002-4703-537X</orcidid><orcidid>https://orcid.org/0000-0001-6538-2474</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0022-1007
ispartof	The Journal of experimental medicine, 2020-09, Vol.217 (9)
issn	0022-1007 1540-9538
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7365736
source	MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects	Betacoronavirus Coronavirus Infections - epidemiology COVID-19 Humans Infectious Disease and Host Defense Inflammation Innate Immunity and Inflammation Pandemics Pneumonia, Viral SARS-CoV-2 Viewpoint
title	Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A23%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blocking%20inflammation%20on%20the%20way:%20Rationale%20for%20CXCR2%20antagonists%20for%20the%20treatment%20of%20COVID-19&rft.jtitle=The%20Journal%20of%20experimental%20medicine&rft.au=Koenig,%20Lars%20M&rft.date=2020-09-07&rft.volume=217&rft.issue=9&rft.issn=0022-1007&rft.eissn=1540-9538&rft_id=info:doi/10.1084/jem.20201342&rft_dat=%3Cproquest_pubme%3E2424998784%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424998784&rft_id=info:pmid/32678432&rfr_iscdi=true